ReviewNeurochemical research2025
Molecular Mechanisms Underlying Chronic High-Dose Ketamine-Induced Apoptosis in the Hippocampus: A Narrative Review.
Review in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.Psychopharmacology · 2026Review
- Molecular Pathogenesis of Memory Impairment in Parkinson's Disease: An Exploration of Underlying Mechanisms.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic high-dose ketamine, widely recognized for its rapid antidepressant effects, poses significant risks to brain health, particularly in the hippocampus, a region critical for learning, memory, and emotional regulation. This narrative review aims to elucidate the molecular mechanisms underlying ketamine-induced apoptosis in hippocampal neurons, providing a comprehensive synthesis of current research findings. We examine how chronic exposure to high doses of ketamine disrupts glutamatergic signaling through NMDA receptor antagonism, leading to an imbalance in excitatory neurotransmission that triggers apoptotic pathways. Additionally, we explore the roles of neuroinflammation and oxidative stress in exacerbating neuronal vulnerability, highlighting the interplay between these mechanisms. The review discusses how chronic ketamine use activates glial cells, resulting in the release of pro-inflammatory cytokines and increased oxidative damage, further promoting neuronal cell death. Furthermore, we consider the implications of altered neurotrophic factor signaling and mitochondrial dysfunction in the context of ketamine’s neurotoxic effects. By integrating these molecular pathways, we provide insights into the critical factors contributing to ketamine-induced apoptosis. Finally, we highlight the need for further research to clarify the dose-response relationship, individual variability in treatment outcomes, and potential neuroprotective strategies. Ultimately, this review emphasizes the importance of balancing the therapeutic benefits of ketamine with its associated risks, advocating for a nuanced understanding of its long-term effects on brain health to inform clinical practices and optimize patient care.
Indexed as
Identifiers
41324812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.